The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $183.06

Today's change+2.28 +1.26%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Jazz Pharmaceuticals PLC

Nasdaq: JAZZ
Last

(U.S.) $183.06

Today's change+2.28 +1.26%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Jazz Pharmaceuticals PLC up (U.S.)$2.28

Jazz Pharmaceuticals PLC closed up Friday by (U.S.)$2.28 or 1.26% to (U.S.)$183.06. Over the last five days, shares have gained 2.84% and are currently 4.16% off of the 52-week high. Shares have outperformed the S&P 500 by 26.87% during the last year.

Key company metrics

  • Open(U.S.) $181.14
  • Previous close(U.S.) $180.78
  • High(U.S.) $184.10
  • Low(U.S.) $180.94
  • Bid / Ask-- / --
  • YTD % change+11.81%
  • Volume366,865
  • Average volume (10-day)469,266
  • Average volume (1-month)500,370
  • Average volume (3-month)673,985
  • 52-week range(U.S.) $127.69 to (U.S.) $191.01
  • Beta0.49
  • Trailing P/E54.39×
  • P/E 1 year forward18.95×
  • Forward PEG1.03×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.37
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.02%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue309328307291
Total other revenue--------
Total revenue309328307291
Gross profit281299280261
Total cost of revenue28292731
Total operating expense193198249217
Selling / general / administrative11210494101
Research & development27259720
Depreciation / amortization25393166
Interest expense (income), net operating--------
Unusual expense (income)1200
Other operating expenses, total--------
Operating income1171305874
Interest income (expense), net non-operating-16-17-15-11
Gain (loss) on sale of assets--------
Other--------
Income before tax1031155063
Income after tax71822644
Income tax, total32342419
Net income71822644
Total adjustments to net income--------
Net income before extra. items71822644
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items71822644
Inc. avail. to common incl. extra. items71822644
Diluted net income71822644
Dilution adjustment--------
Diluted weighted average shares63726362
Diluted EPS excluding extraordinary itemsvalue per share1.121.130.410.70
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.131.200.260.60